Director at CytomX (NASDAQ: CTMX) receives 59,000-stock option award
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CytomX Therapeutics director Mani Mohindru received a grant of 59,000 stock options for Common Stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036. All 59,000 options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, subject to continuous service as a director.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Mohindru Mani
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 59,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 59,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 59,000 options
Exercise price: $2.96 per share
Underlying shares: 59,000 shares
+2 more
5 metrics
Option grant size
59,000 options
Stock Option (Right to Buy) granted to director
Exercise price
$2.96 per share
Conversion or exercise price of options
Underlying shares
59,000 shares
Underlying Common Stock tied to options
Expiration date
June 16, 2036
Option expiration
Post-grant derivative holding
59,000 options
Total derivative securities following transaction
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, Annual Meeting of the Issuer's stockholders
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Annual Meeting of the Issuer's stockholders financial
"the date of the 2027 Annual Meeting of the Issuer's stockholders"
FAQ
What did Mani Mohindru report in the CytomX (CTMX) Form 4 filing?
The filing reports a grant of 59,000 stock options to director Mani Mohindru. These options give the right to buy CytomX Common Stock at a fixed price, subject to vesting conditions and an expiration date.
What is the exercise price of the new CytomX (CTMX) stock options?
The granted options have an exercise price of $2.96 per share. This is the price at which the holder may purchase CytomX Common Stock once the options vest and before they expire, assuming all vesting conditions are satisfied.
When do Mani Mohindru’s CytomX (CTMX) options vest?
All 59,000 options vest 100% on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders. Vesting requires continuous service as a director until that vesting date.
When do the CytomX (CTMX) stock options granted to Mani Mohindru expire?
The options expire on June 16, 2036. After this expiration date, any unexercised options become worthless, so exercises must occur between vesting and this expiration, subject to applicable trading and company policies.
How many CytomX (CTMX) options does Mani Mohindru hold after this grant?
Following the reported transaction, Mani Mohindru holds 59,000 stock options directly. This filing shows only this option position, which corresponds to the newly granted award disclosed in the Form 4 data.